Most Read Articles
Naomi Rodrig, 15 Jun 2016
An interim analysis from the multinational phase III CASTOR trial, presented recently at the 2016 American Society of Clinical Oncology (ASCO) Annual Meeting, showed that adding daratumumab to the standard two-drug regimen of bortezomib and dexamethasone markedly improved outcomes of patients with recurrent or refractory multiple myeloma.
Saras Ramiya, 14 Nov 2017
Accord Healthcare launches Accord Bortezomib® (bortezomib 3.5 mg per vial) for the treatment of patients with multiple myeloma and mantle cell lymphoma in Malaysia.
Su Ping Chuah, 01 Aug 2014

New immune therapies with new targets that can induce long-term remission in patients with advanced cutaneous T-cell lymphoma (CTCL) are needed, says an expert.

Radha Chitale, 01 Aug 2014

German experts came together to update guidelines on melanoma management and create consensus out of fragmented standards of care by experts across multiple fields.

Accelerated elozutumab infusion safe for multiple myeloma

08 Sep 2017

Accelerated administration of elotuzumab for multiple myeloma (MM) or relapsed/refractory MM (RRMM) is safe and produces no grade 3 or 4 infusion reactions (IRs), a phase 2 study shows.

Investigators involved 70 adults with active and newly diagnosed MM or RRMM (median age 67.5 years). Of these, 47 percent (n=33) had received prior treatments for MM, the most common of which was bortezomib (41 percent).

Infusion rate of the first dose of elotuzumab during cycle 1 was increased from 0.5 to 2 mL/min in the absence of IRs. Rates were increased from 3 to 4 mL/min during dose 2 and to mL/min for all succeeding doses. Of all infusions, 87 percent (n=968) were delivered at the maximum rate of 5 mL/min.

There were no reported cases of the primary outcome of grade 3 or 4 IRs by the end of cycle 2. Only two IRs were reported, both of which manifested during the 2 mL/min infusion rate. One patient experienced a nonspecific grade 2 infusion-related reaction, while the other had a grade 1 pyrexia.

Infusion was interrupted only in the case of the grade 2 IR but was resumed after resolution. No treatments were discontinued due to IRs.

The most common adverse event (AE) was infection which was observed in 60 percent (n=42) of the participants. This was followed by fatigue (50 percent; n=35) and diarrhoea (31 percent; n=22). Eight cases of grade 4 AEs were reported and 13 patients discontinued treatment because of AEs.

A total of 27 patients experienced severe AEs, the most common of which were pneumonia and atrial fibrillation which were observed in three patients each. There was a total of five deaths caused by disease progression, fatal bleeding, respiratory failure and ischaemic bowel syndrome.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Oncology - Malaysia digital copy today!
DOWNLOAD
Editor's Recommendations
Most Read Articles
Naomi Rodrig, 15 Jun 2016
An interim analysis from the multinational phase III CASTOR trial, presented recently at the 2016 American Society of Clinical Oncology (ASCO) Annual Meeting, showed that adding daratumumab to the standard two-drug regimen of bortezomib and dexamethasone markedly improved outcomes of patients with recurrent or refractory multiple myeloma.
Saras Ramiya, 14 Nov 2017
Accord Healthcare launches Accord Bortezomib® (bortezomib 3.5 mg per vial) for the treatment of patients with multiple myeloma and mantle cell lymphoma in Malaysia.
Su Ping Chuah, 01 Aug 2014

New immune therapies with new targets that can induce long-term remission in patients with advanced cutaneous T-cell lymphoma (CTCL) are needed, says an expert.

Radha Chitale, 01 Aug 2014

German experts came together to update guidelines on melanoma management and create consensus out of fragmented standards of care by experts across multiple fields.